| scholarly article | Q13442814 |
| P2093 | author name string | Anna Boyajyan | |
| Roksana Zakharyan | |||
| P2860 | cites work | Schizophrenia patients with a history of childhood trauma have a pro-inflammatory phenotype | Q57513593 |
| Haplotypes in the expression quantitative trait locus of interleukin-1β gene are associated with schizophrenia | Q57539100 | ||
| No association between the promoter variants of tumor necrosis factor alpha (TNF-α) and schizophrenia in Chinese Han population | Q57590016 | ||
| Blood-cerebrospinal fluid barrier in schizophrenic patients | Q57781219 | ||
| Association of an Interleukin-1β Genetic Polymorphism With Altered Brain Structure in Patients With Schizophrenia | Q58444648 | ||
| Evaluation of association of SNPs in the TNF alpha gene region with schizophrenia | Q59206084 | ||
| Theories of schizophrenia: a genetic-inflammatory-vascular synthesis | Q24800460 | ||
| Cytokine hypothesis of schizophrenia pathogenesis: evidence from human studies and animal models | Q27687241 | ||
| Association between IL-1beta -511C/T and IL-1RA (86bp)n repeats polymorphisms and schizophrenia | Q28210488 | ||
| Complement C4B protein in schizophrenia | Q28248411 | ||
| Elevated maternal interleukin-8 levels and risk of schizophrenia in adult offspring | Q28259611 | ||
| Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor | Q28261811 | ||
| CCL2 polymorphisms are associated with serum monocyte chemoattractant protein-1 levels and myocardial infarction in the Framingham Heart Study | Q28268514 | ||
| Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database | Q28285397 | ||
| Classical pathway complement activity in schizophrenia | Q28301057 | ||
| The interaction of nuclear factor-kappa B and cytokines is associated with schizophrenia | Q28303000 | ||
| Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha in schizophrenic patients, relation with symptomatology and responsiveness to risperidone treatment | Q28350052 | ||
| Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects | Q28657600 | ||
| Inflammation-related genes up-regulated in schizophrenia brains | Q33297810 | ||
| Analysis of peripheral immune activation in schizophrenia using quantitative reverse-transcription polymerase chain reaction (RT-PCR) | Q33749249 | ||
| Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls | Q33803377 | ||
| Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume | Q33849008 | ||
| ATA homozigosity in the IL-10 gene promoter is a risk factor for schizophrenia in Spanish females: a case control study | Q33928098 | ||
| Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia | Q33941953 | ||
| Functional characterization of the complement receptor type 1 and its circulating ligands in patients with schizophrenia. | Q34002943 | ||
| Association of C1QB gene polymorphism with schizophrenia in Armenian population. | Q34032829 | ||
| The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder | Q34088944 | ||
| Cytokine and growth factor involvement in schizophrenia--support for the developmental model | Q34111013 | ||
| Anti-Inflammatory properties of antipsychotics via microglia modulations: are antipsychotics a 'fire extinguisher' in the brain of schizophrenia? | Q34194961 | ||
| Immunoregulation of microglial functional properties. | Q34349268 | ||
| Prefrontal abnormality of schizophrenia revealed by DNA microarray: impact on glial and neurotrophic gene expression | Q34367536 | ||
| Immune involvement in schizophrenia and autism: etiology, pathology and animal models | Q34602964 | ||
| Schizophrenia, "just the facts" what we know in 2008. 2. Epidemiology and etiology | Q34783101 | ||
| A unifying hypothesis of schizophrenia: abnormal immune system development may help explain roles of prenatal hazards, post-pubertal onset, stress, genes, climate, infections, and brain dysfunction | Q35008345 | ||
| Cytokines: powerful regulators of glial cell activation | Q35064076 | ||
| Effect of the interleukin-1β gene on dorsolateral prefrontal cortex function in schizophrenia: a genetic neuroimaging study. | Q48451200 | ||
| Altered levels of acute phase proteins in the plasma of patients with schizophrenia | Q48515944 | ||
| Circulating levels of sTNFR1 as a marker of severe clinical course in schizophrenia. | Q48528979 | ||
| Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer's disease | Q48690661 | ||
| Increased annexin-V and decreased TNF-α serum levels in chronic-medicated patients with schizophrenia | Q49070622 | ||
| Association study of interleukin 2 (IL2) and IL4 with schizophrenia in a Japanese population | Q49161148 | ||
| Schizophrenia and the life course: national findings on gender differences in disability and service use. | Q50140618 | ||
| Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. | Q50743494 | ||
| Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358Ala polymorphism of the IL-6 receptor gene in schizophrenic patients. | Q50796980 | ||
| Decreased interleukin-2 production in Korean schizophrenic patients. | Q50889661 | ||
| Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effects of clozapine treatment. | Q50942850 | ||
| Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients. | Q51000957 | ||
| Tumor necrosis factor alpha gene-G308A polymorphism associated with bipolar I disorder in the Korean population. | Q51033539 | ||
| C-reactive protein is elevated in schizophrenia. | Q51290721 | ||
| Impact of antipsychotics on cytokine production in-vitro. | Q51461858 | ||
| Serum interleukin 1 alpha and interleukin 2 levels in patients with schizophrenia. | Q51541451 | ||
| Increased complement classical and mannan-binding lectin pathway activities in schizophrenia. | Q51914518 | ||
| Polymorphisms of interleukin‐4 promoter and receptor gene for schizophrenia in the Korean population | Q51948694 | ||
| No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia. | Q51952057 | ||
| Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. | Q51953367 | ||
| Interleukin-1 alpha and interleukin-2 in cerebrospinal fluid of schizophrenic subjects. | Q52036353 | ||
| MCP-1 in Alzheimer's disease patients: A-2518G polymorphism and serum levels. | Q53263592 | ||
| Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. | Q53411974 | ||
| MCP-1 gene (SCYA2) and schizophrenia: a case-control association study. | Q53884364 | ||
| Interleukin-6 promoter polymorphism and plasma levels in patients with schizophrenia. | Q54310862 | ||
| Monocyte chemoattractant protein-1 in schizophrenia: -2518A/G genetic variant and protein levels in Armenian population. | Q54318857 | ||
| Potential role of Neuregulin 1 and TNF-alpha (-308) polymorphism in schizophrenia patients visiting hospitals in Lahore, Pakistan. | Q54398991 | ||
| Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia | Q56767047 | ||
| Association between −G308A tumor necrosis factor alpha gene polymorphism and schizophrenia | Q56767241 | ||
| Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs | Q56767386 | ||
| Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs | Q56767449 | ||
| Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers | Q56767487 | ||
| Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression | Q56767504 | ||
| Cellular and humoral immune system in schizophrenia: a conceptual re-evaluation | Q35073823 | ||
| Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity | Q35162073 | ||
| Possible association between interleukin-1β gene and schizophrenia in a Japanese population. | Q35200533 | ||
| Is damage in central nervous system due to inflammation? | Q35832286 | ||
| Maternal immune activation by poly I:C induces expression of cytokines IL-1β and IL-13, chemokine MCP-1 and colony stimulating factor VEGF in fetal mouse brain | Q36146434 | ||
| Elevated levels of circulating IL-18BP and perturbed regulation of IL-18 in schizophrenia | Q36281530 | ||
| Apoptosis in schizophrenia: pathophysiologic and therapeutic considerations | Q36448252 | ||
| Gene expression profiling in schizophrenia and related mental disorders. | Q36535686 | ||
| Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission | Q36633620 | ||
| Microglial control of neuronal death and synaptic properties | Q36654256 | ||
| Roles of glia-derived cytokines on neuronal degeneration and regeneration | Q36693990 | ||
| Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan | Q36725461 | ||
| Serum and gene expression profile of cytokines in first-episode psychosis | Q36910378 | ||
| Complement genetics, deficiencies, and disease associations | Q36922946 | ||
| Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review | Q37001984 | ||
| Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. | Q37095956 | ||
| A review of the fetal brain cytokine imbalance hypothesis of schizophrenia. | Q37137212 | ||
| The complement system in schizophrenia | Q37193661 | ||
| Metabolic profile of antipsychotic-naive individuals with non-affective psychosis | Q37245422 | ||
| Review: Role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. | Q37348864 | ||
| Is schizophrenia the price of human central nervous system complexity? | Q37351722 | ||
| Biological risks for neurological abnormalities associated with hyperbilirubinemia. | Q37379760 | ||
| Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. | Q37541981 | ||
| Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy | Q37546096 | ||
| A role for glutathione in the pathophysiology of bipolar disorder and schizophrenia? Animal models and relevance to clinical practice. | Q37581709 | ||
| Cytokines and CNS development | Q37617628 | ||
| Anti-inflammatory signaling in schizophrenia | Q37888032 | ||
| Immune system in the brain: a modulatory role on dendritic spine morphophysiology? | Q38006707 | ||
| Schizophrenia: linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression. | Q38026641 | ||
| Blood-brain barrier dysfunction in brain diseases: clinical experience | Q38058370 | ||
| DNA methylation status of SOX10 correlates with its downregulation and oligodendrocyte dysfunction in schizophrenia. | Q38325560 | ||
| Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia | Q38516733 | ||
| C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia | Q39000943 | ||
| Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders | Q39744231 | ||
| Risperidone significantly inhibits interferon-gamma-induced microglial activation in vitro | Q40158583 | ||
| Influence of the IL-1Ra gene polymorphism on in vivo synthesis of IL-1Ra and IL-1beta after live yellow fever vaccination | Q40597122 | ||
| Regulation of the acute phase response by cytokines | Q40840600 | ||
| THE LACTIC ACID AND GLUTATHIONE CONTENT OF THE BLOOD OF SCHIZOPHRENIC PATIENTS. | Q40978848 | ||
| Cytokines and the immune response | Q41115964 | ||
| Abnormalities in serum concentrations of interleukin-2, interferon-alpha and interferon-gamma in schizophrenia not detected | Q41116815 | ||
| Regulation of the HPA axis by cytokines | Q41198729 | ||
| Immune-inflammatory markers in schizophrenia: comparison to normal controls and effects of clozapine | Q42283978 | ||
| Clozapine Mobilizes CD34+ Hematopoietic Stem and Progenitor Cells and Increases Plasma Concentration of Interleukin 6 in Patients With Schizophrenia | Q42918754 | ||
| Tyrosine hydroxylase, interleukin-1beta and tumor necrosis factor-alpha are overexpressed in peripheral blood mononuclear cells from schizophrenia patients as determined by semi-quantitative analysis | Q43196311 | ||
| Neuroinflammation in schizophrenia-related psychosis: a PET study. | Q43259552 | ||
| Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia | Q43444866 | ||
| A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro | Q43458583 | ||
| Neuroleptics normalize increased release of interleukin- 1 beta and tumor necrosis factor-alpha from monocytes in schizophrenia | Q43663330 | ||
| Association of interleukin 2 (IL-2), interleukin 6 (IL-6), and TNF-alpha (TNFα) gene polymorphisms with paranoid schizophrenia in a Polish population. | Q43740839 | ||
| Association between promoter variants of interleukin-18 and schizophrenia in a Han Chinese population | Q44073652 | ||
| IL-2 and IL-4 polymorphisms as candidate genes in schizophrenia | Q44591382 | ||
| Lack of association of IL-6 (-174 G>C) and TNF-α (-238 G>A) variants with paranoid schizophrenia in Indian Bengalee population | Q44849443 | ||
| Cytokine profiles in schizophrenic patients treated with risperidone: a 3-month follow-up study | Q45711971 | ||
| A study of the complement system in psychiatric patients | Q45838120 | ||
| Increased oxidative stress in the anterior cingulate cortex of subjects with bipolar disorder and schizophrenia. | Q45923132 | ||
| CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers. | Q45996585 | ||
| Cytokine changes and tryptophan metabolites in medication-naïve and medication-free schizophrenic patients. | Q46038610 | ||
| Altered interleukin-2 production in schizophrenia: association between clinical state and autoantibody production | Q46488072 | ||
| Interleukin-12 plasma levels in drug-naïve patients with a first episode of psychosis: effects of antipsychotic drugs | Q46776187 | ||
| Interaction analysis between 5-HTTLPR and TNFA -238/-308 polymorphisms in schizophrenia. | Q46776543 | ||
| TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment | Q47351658 | ||
| Monocyte chemoattractant protein-1 promoter -2518 polymorphism and schizophrenia in the Korean population | Q47418701 | ||
| Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia | Q47577999 | ||
| Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication | Q47672132 | ||
| Increased levels of CD8+ and CD4+ 45RA+ lymphocytes in schizophrenic patients | Q47951449 | ||
| Plasma and cerebrospinal fluid interleukin-1 beta and interleukin-6 in hospitalized schizophrenic patients. | Q48220306 | ||
| Polymorphisms of the interleukin-1 gene complex in schizophrenia | Q48234448 | ||
| Association study of IL10, IL1beta, and IL1RN and schizophrenia using tag SNPs from a comprehensive database: suggestive association with rs16944 at IL1beta | Q48435281 | ||
| P433 | issue | 3 | |
| P921 | main subject | inflammation | Q101991 |
| schizophrenia | Q41112 | ||
| P304 | page(s) | 174-187 | |
| P577 | publication date | 2013-09-16 | |
| P1433 | published in | World Journal of Biological Psychiatry | Q15759917 |
| P1476 | title | Inflammatory cytokine network in schizophrenia | |
| P478 | volume | 15 |
| Q47895892 | Abnormal gene and protein expression of inflammatory cytokines in the postmortem brain of schizophrenia patients. |
| Q50561727 | Anti-inflammatory strategies in the treatment of schizophrenia. |
| Q45607380 | Autoimmunity and autoinflammation: A systems view on signaling pathway dysregulation profiles |
| Q37456857 | Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders |
| Q39311356 | C3 Polymorphism Influences Circulating Levels of C3, ASP and Lipids in Schizophrenic Patients |
| Q47938598 | Changing the Diagnostic Concept of Schizophrenia: The NIMH Research Domain Criteria Initiative. |
| Q37423045 | Cryoglobulins as potential triggers of inflammation in schizophrenia |
| Q42251222 | DNA Methylation Changes in Intron 1 of Triggering Receptor Expressed on Myeloid Cell 2 in Japanese Schizophrenia Subjects |
| Q40350162 | Effects of olanzapine on LPS-induced inflammation in rat primary glia cells |
| Q89147867 | Epigallocatechin gallate improves airway inflammation through TGF‑β1 signaling pathway in asthmatic mice |
| Q38966344 | Human whole-blood culture system for ex vivo characterization of designer-cell function |
| Q37083097 | Proinflammatory cytokines and their membrane-bound receptors are altered in the lymphocytes of schizophrenia patients |
| Q34942662 | Regulation of interleukin-6 and leptin in schizophrenia patients: a preliminary analysis |
| Q35168712 | Sex differences in TGFB-β signaling with respect to age of onset and cognitive functioning in schizophrenia |
| Q37410987 | Supra-therapeutic plasma concentrations of haloperidol induce moderate inhibition of lipopolysaccharide-induced interleukin-8 release in human monocytes |
| Q38232366 | The neurobiology and treatment of first-episode schizophrenia |
| Q28306989 | β-phenylethylamine, a small molecule with a large impact |
Search more.